Vacina da Curevac com apenas 47% de eficácia nos ensaios ...

ECO Economia Online - 17 Jun 2021
A vacina contra a Covid-19 que está a ser desenvolvida pela alemã Curevac revelou apenas 47% de eficácia, segundo a análise preliminar dos ensaios ...

CureVac: a vacina alemã de RNA que pode ser armazenada em geladeira comum

Revista Galileu - 08 May 2021
CureVac: a vacina alemã de RNA que pode ser armazenada em geladeira comum ...

CureVac: o que explica o resultado fraco dessa vacina de mRNA?

Olhar Digital - 21 Jun 2021
CureVac: o que explica o resultado fraco dessa vacina de mRNA? ...

A primeira derrota do RNA contra o coronavírus

EL PAÍS Brasil - 26 Jun 2021
A primeira derrota do RNA contra o coronavírus ...

Farmacêuticas GSK e CureVac desenvolvem em conjunto nova vacina

Agência Brasil - 03 Feb 2021
Farmacêuticas GSK e CureVac desenvolvem em conjunto nova vacina ...

GSK e CureVac firmam parceria para nova geração de vacina

medicinasa.com.br - 09 Feb 2021
GSK e CureVac firmam parceria para nova geração de vacina ...

GSK e CureVac dizem que vacina contra Covid-19 é promissora em teste com macacos

Época NEGÓCIOS - 16 Aug 2021
GSK e CureVac dizem que vacina contra Covid-19 é promissora em teste com macacos ...

Bayer vai produzir vacina da CureVac contra Covid-19

Folha de Pernambuco - 01 Feb 2021
Bayer vai produzir vacina da CureVac contra Covid-19 ...

Novartis vai auxiliar na fabricação de vacina da CureVac contra a Covid-19

Olhar Digital - 08 Mar 2021
Novartis vai auxiliar na fabricação de vacina da CureVac contra a Covid-19 ...

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business ...

CureVac - 14 Nov 2023
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business ... ...

German Federal Patent Court changes its mind on CureVac mRNA patent

JUVE Patent - 19 Dec 2023
German Federal Patent Court changes its mind on CureVac mRNA patent ...

Bayer e CureVac esperam ter vacina contra Covid-19 no segundo trimestre

G1 - 27 Jan 2021
Bayer e CureVac esperam ter vacina contra Covid-19 no segundo trimestre ...

CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech

CureVac - 19 May 2023
CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech ...

Düsseldorf Regional Court waits for validity judgments in CureVac v BioNTech

JUVE Patent - 17 Aug 2023
Düsseldorf Regional Court waits for validity judgments in CureVac v BioNTech ...

CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in ...

CureVac - 01 Nov 2023
CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in ... ...

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update

CureVac - 30 May 2023
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update ...

CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma

CureVac - 20 Jun 2023
CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma ...

CureVac to Report Third Quarter and First Nine Months 2023 Financial Results and Business Updates on November ...

CureVac - 31 Oct 2023
CureVac to Report Third Quarter and First Nine Months 2023 Financial Results and Business Updates on November ... ...

CureVac Appoints Alexander Zehnder as CEO From April 1, 2023

CureVac - 09 Jan 2023
CureVac Appoints Alexander Zehnder as CEO From April 1, 2023 ...

CureVac Announces Changes of CDO - Myriam Mendila to succeed Klaus Edvardsen

CureVac - 08 Jun 2022
CureVac Announces Changes of CDO - Myriam Mendila to succeed Klaus Edvardsen ...

CureVac